ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology

Stefanie Corradini; Filippo Alongi; Nicolaus Andratschke; David Azria; Omar Bohoudi; Luca Boldrini; Anna Bruynzeel; Juliane Hörner-Rieber; Ina Jürgenliemk-Schulz; Frank Lagerwaard; Helen McNair; Bas Raaymakers; Tine Schytte; Alison Tree; Vincenzo Valentini; Lotte Wilke; Daniel Zips; Claus Belka

doi:10.1016/j.radonc.2021.03.025

ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology

Stefanie Corradini^*
, Filippo Alongi
, Nicolaus Andratschke
, David Azria
, Omar Bohoudi
, Luca Boldrini
, Anna Bruynzeel
, Juliane Hörner-Rieber
, Ina Jürgenliemk-Schulz
, Frank Lagerwaard
, Helen McNair
, Bas Raaymakers
, Tine Schytte
, Alison Tree
, Vincenzo Valentini
, Lotte Wilke
, Daniel Zips
, Claus Belka

^*Kontaktforfatter

KI, OUH, Forskningsenhed for Onkologi (Odense)

Ludwig-Maximilian University of Munich
Brescia University
University Hospital Zurich
Université de Montpellier – Université Paul Valéry – EPHE
University of Amsterdam
Gemelli University Hospital
Heidelberg University
University Medical Center Utrecht
The Royal Marsden NHS Foundation Trust
Eberhard Karls University of Tübingen

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

263 Downloads (Pure)

Abstract

Online magnetic resonance-guided radiotherapy (oMRgRT) represents one of the most innovative applications of current image-guided radiation therapy (IGRT). The revolutionary concept of oMRgRT systems is the ability to acquire MR images for adaptive treatment planning and also online imaging during treatment delivery. The daily adaptive planning strategies allow to improve targeting accuracy while avoiding critical structures. This ESTRO-ACROP recommendation aims to provide an overview of available systems and guidance for best practice in the implementation phase of hybrid MR-linac systems. Unlike the implementation of other radiotherapy techniques, oMRgRT adds the MR environment to the daily practice of radiotherapy, which might be a new experience for many centers. New issues and challenges that need to be thoroughly explored before starting clinical treatments will be highlighted.

Originalsprog	Engelsk
Tidsskrift	Radiotherapy & Oncology
Vol/bind	159
Sider (fra-til)	146-154
ISSN	0167-8140
DOI	https://doi.org/10.1016/j.radonc.2021.03.025
Status	Udgivet - jun. 2021

Bibliografisk note

Funding Information:
CB and SC have received research grants and speaker fees/travel support from Elekta, Viewray and Brainlab. FA is a consultant and has received speaker honoraria from Elekta, Varian and Boston scientific. NA has received funding from Brainlab and ViewRay and speaker fees/travel support from ViewRay. DA has received institutional research funding from ViewRay. OB has received speaker fees from ViewRay. LB has received research grants from Varian and ViewRay and speaker fees/travel support from ViewRay. AB has received speaker fees and travel support from ViewRay inc. Amsterdam UMC has research agreements with ViewRay inc. JHR has received speaker fees and travel reimbursement from ViewRay Inc, as well as travel reimbursement form IntraOP Medical and Elekta Instrument AB outside the submitted work. FL has received speaker fees and travel support from ViewRay inc. Amsterdam UMC has research agreements with ViewRay inc. HMcN is funded by a National Institute for Health Research and Health Education England (HEE/NIHR), Senior Clinical Lecturer award. BR has received research support and/or funding from Elekta, Philips, Modus QA, Sun Nuclear, IBA, PTW, Scandidos and speaker fees from Elekta. AT has received research funding from Elekta, Varian and Accuray, and speaker fees/travel grants from Elekta and Genesis Healthcare. VV has received departmental research grants from Varian Medical Systems, ViewRay Inc., Elekta, Merck-Serono, Roche. DZ receives within the framework of research agreements financial and technical support as well as sponsoring for travels and scientific symposia from Elekta, Philips, Siemens, PTW and Sennewald. Research in MRgRT is funded by the German Research Council (DFG, ZI 736/2-1; PAK997/1). The other authors declare that they have no competing interests.

Funding Information:
AT would like to thank the Rosetrees Trust, Cancer Research UK (grant C33589/A28284) and the MRC for their support. This work represents independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Finansiering

CB and SC have received research grants and speaker fees/travel support from Elekta, Viewray and Brainlab. FA is a consultant and has received speaker honoraria from Elekta, Varian and Boston scientific. NA has received funding from Brainlab and ViewRay and speaker fees/travel support from ViewRay. DA has received institutional research funding from ViewRay. OB has received speaker fees from ViewRay. LB has received research grants from Varian and ViewRay and speaker fees/travel support from ViewRay. AB has received speaker fees and travel support from ViewRay inc. Amsterdam UMC has research agreements with ViewRay inc. JHR has received speaker fees and travel reimbursement from ViewRay Inc, as well as travel reimbursement form IntraOP Medical and Elekta Instrument AB outside the submitted work. FL has received speaker fees and travel support from ViewRay inc. Amsterdam UMC has research agreements with ViewRay inc. HMcN is funded by a National Institute for Health Research and Health Education England (HEE/NIHR), Senior Clinical Lecturer award. BR has received research support and/or funding from Elekta, Philips, Modus QA, Sun Nuclear, IBA, PTW, Scandidos and speaker fees from Elekta. AT has received research funding from Elekta, Varian and Accuray, and speaker fees/travel grants from Elekta and Genesis Healthcare. VV has received departmental research grants from Varian Medical Systems, ViewRay Inc., Elekta, Merck-Serono, Roche. DZ receives within the framework of research agreements financial and technical support as well as sponsoring for travels and scientific symposia from Elekta, Philips, Siemens, PTW and Sennewald. Research in MRgRT is funded by the German Research Council (DFG, ZI 736/2-1; PAK997/1). The other authors declare that they have no competing interests. CB and SC have received research grants and speaker fees/travel support from Elekta, Viewray and Brainlab. FA is a consultant and has received speaker honoraria from Elekta, Varian and Boston scientific. NA has received funding from Brainlab and ViewRay and speaker fees/travel support from ViewRay. DA has received institutional research funding from ViewRay. OB has received speaker fees from ViewRay. LB has received research grants from Varian and ViewRay and speaker fees/travel support from ViewRay. AB has received speaker fees and travel support from ViewRay inc. Amsterdam UMC has research agreements with ViewRay inc. JHR has received speaker fees and travel reimbursement from ViewRay Inc, as well as travel reimbursement form IntraOP Medical and Elekta Instrument AB outside the submitted work. FL has received speaker fees and travel support from ViewRay inc. Amsterdam UMC has research agreements with ViewRay inc. HMcN is funded by a National Institute for Health Research and Health Education England (HEE/NIHR), Senior Clinical Lecturer award. BR has received research support and/or funding from Elekta, Philips, Modus QA, Sun Nuclear, IBA, PTW, Scandidos and speaker fees from Elekta. AT has received research funding from Elekta, Varian and Accuray, and speaker fees/travel grants from Elekta and Genesis Healthcare. VV has received departmental research grants from Varian Medical Systems, ViewRay Inc., Elekta, Merck-Serono, Roche. DZ receives within the framework of research agreements financial and technical support as well as sponsoring for travels and scientific symposia from Elekta, Philips, Siemens, PTW and Sennewald. Research in MRgRT is funded by the German Research Council (DFG, ZI 736/2-1; PAK997/1). The other authors declare that they have no competing interests. AT would like to thank the Rosetrees Trust, Cancer Research UK (grant C33589/A28284) and the MRC for their support. This work represents independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Dokumenter og links

10.1016/j.radonc.2021.03.025

Open Access VersionAccepteret manuskript, 278 KBLicens: CC BY-NC-ND

SDU link

Tjek adgangen til materialet i Syddansk Universitetsbiblioteks søgemaskine

Citationsformater

Corradini, S., Alongi, F., Andratschke, N., Azria, D., Bohoudi, O., Boldrini, L., Bruynzeel, A., Hörner-Rieber, J., Jürgenliemk-Schulz, I., Lagerwaard, F., McNair, H., Raaymakers, B., Schytte, T., Tree, A., Valentini, V., Wilke, L., Zips, D., & Belka, C. (2021). ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology. Radiotherapy & Oncology, 159, 146-154. https://doi.org/10.1016/j.radonc.2021.03.025

@article{fe4e1e7a333740b5a56f6a1bd5791c2a,

title = "ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology",

abstract = "Online magnetic resonance-guided radiotherapy (oMRgRT) represents one of the most innovative applications of current image-guided radiation therapy (IGRT). The revolutionary concept of oMRgRT systems is the ability to acquire MR images for adaptive treatment planning and also online imaging during treatment delivery. The daily adaptive planning strategies allow to improve targeting accuracy while avoiding critical structures. This ESTRO-ACROP recommendation aims to provide an overview of available systems and guidance for best practice in the implementation phase of hybrid MR-linac systems. Unlike the implementation of other radiotherapy techniques, oMRgRT adds the MR environment to the daily practice of radiotherapy, which might be a new experience for many centers. New issues and challenges that need to be thoroughly explored before starting clinical treatments will be highlighted.",

keywords = "Adaptation, Implementation, MR-guided radiotherapy, MR-Linac, Online adaptive, Radiotherapy",

author = "Stefanie Corradini and Filippo Alongi and Nicolaus Andratschke and David Azria and Omar Bohoudi and Luca Boldrini and Anna Bruynzeel and Juliane H{\"o}rner-Rieber and Ina J{\"u}rgenliemk-Schulz and Frank Lagerwaard and Helen McNair and Bas Raaymakers and Tine Schytte and Alison Tree and Vincenzo Valentini and Lotte Wilke and Daniel Zips and Claus Belka",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier B.V.",

year = "2021",

month = jun,

doi = "10.1016/j.radonc.2021.03.025",

language = "English",

volume = "159",

pages = "146--154",

journal = "Radiotherapy \& Oncology",

issn = "0167-8140",

publisher = "Elsevier",

}

Corradini, S, Alongi, F, Andratschke, N, Azria, D, Bohoudi, O, Boldrini, L, Bruynzeel, A, Hörner-Rieber, J, Jürgenliemk-Schulz, I, Lagerwaard, F, McNair, H, Raaymakers, B, Schytte, T, Tree, A, Valentini, V, Wilke, L, Zips, D & Belka, C 2021, 'ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology', Radiotherapy & Oncology, bind 159, s. 146-154. https://doi.org/10.1016/j.radonc.2021.03.025

TY - JOUR

T1 - ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology

AU - Corradini, Stefanie

AU - Alongi, Filippo

AU - Andratschke, Nicolaus

AU - Azria, David

AU - Bohoudi, Omar

AU - Boldrini, Luca

AU - Bruynzeel, Anna

AU - Hörner-Rieber, Juliane

AU - Jürgenliemk-Schulz, Ina

AU - Lagerwaard, Frank

AU - McNair, Helen

AU - Raaymakers, Bas

AU - Schytte, Tine

AU - Tree, Alison

AU - Valentini, Vincenzo

AU - Wilke, Lotte

AU - Zips, Daniel

AU - Belka, Claus

PY - 2021/6

Y1 - 2021/6

N2 - Online magnetic resonance-guided radiotherapy (oMRgRT) represents one of the most innovative applications of current image-guided radiation therapy (IGRT). The revolutionary concept of oMRgRT systems is the ability to acquire MR images for adaptive treatment planning and also online imaging during treatment delivery. The daily adaptive planning strategies allow to improve targeting accuracy while avoiding critical structures. This ESTRO-ACROP recommendation aims to provide an overview of available systems and guidance for best practice in the implementation phase of hybrid MR-linac systems. Unlike the implementation of other radiotherapy techniques, oMRgRT adds the MR environment to the daily practice of radiotherapy, which might be a new experience for many centers. New issues and challenges that need to be thoroughly explored before starting clinical treatments will be highlighted.

AB - Online magnetic resonance-guided radiotherapy (oMRgRT) represents one of the most innovative applications of current image-guided radiation therapy (IGRT). The revolutionary concept of oMRgRT systems is the ability to acquire MR images for adaptive treatment planning and also online imaging during treatment delivery. The daily adaptive planning strategies allow to improve targeting accuracy while avoiding critical structures. This ESTRO-ACROP recommendation aims to provide an overview of available systems and guidance for best practice in the implementation phase of hybrid MR-linac systems. Unlike the implementation of other radiotherapy techniques, oMRgRT adds the MR environment to the daily practice of radiotherapy, which might be a new experience for many centers. New issues and challenges that need to be thoroughly explored before starting clinical treatments will be highlighted.

KW - Adaptation

KW - Implementation

KW - MR-guided radiotherapy

KW - MR-Linac

KW - Online adaptive

KW - Radiotherapy

U2 - 10.1016/j.radonc.2021.03.025

DO - 10.1016/j.radonc.2021.03.025

M3 - Journal article

C2 - 33775715

AN - SCOPUS:85103938763

SN - 0167-8140

VL - 159

SP - 146

EP - 154

JO - Radiotherapy & Oncology

JF - Radiotherapy & Oncology

ER -

ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology

Abstract

Bibliografisk note

Finansiering

Dokumenter og links

SDU link

Fingeraftryk

Citationsformater